391 related articles for article (PubMed ID: 18539972)
21. Chronic versus acute myelogenous leukemia: a question of self-renewal.
Jamieson CH; Weissman IL; Passegué E
Cancer Cell; 2004 Dec; 6(6):531-3. PubMed ID: 15607956
[TBL] [Abstract][Full Text] [Related]
22. Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.
Holm F; Hellqvist E; Mason CN; Ali SA; Delos-Santos N; Barrett CL; Chun HJ; Minden MD; Moore RA; Marra MA; Runza V; Frazer KA; Sadarangani A; Jamieson CH
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15444-9. PubMed ID: 26621726
[TBL] [Abstract][Full Text] [Related]
23. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
24. The fundamental prevalence of chronic myeloid leukemia-generating clonogenic cells in the light of the neutrality theory of evolution.
Jankovic GM; Pavlovic M; Vukomanovic DJ; Colovic MD; Lazarevic V
Blood Cells Mol Dis; 2001; 27(5):913-7. PubMed ID: 11783955
[TBL] [Abstract][Full Text] [Related]
25. Normal and leukaemic stem cells.
Bonnet D
Br J Haematol; 2005 Aug; 130(4):469-79. PubMed ID: 16098060
[TBL] [Abstract][Full Text] [Related]
26. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
27. Novel combination treatments targeting chronic myeloid leukemia stem cells.
Al Baghdadi T; Abonour R; Boswell HS
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):94-105. PubMed ID: 22178144
[TBL] [Abstract][Full Text] [Related]
28. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
[TBL] [Abstract][Full Text] [Related]
29. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
30. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
Krivtsov AV; Twomey D; Feng Z; Stubbs MC; Wang Y; Faber J; Levine JE; Wang J; Hahn WC; Gilliland DG; Golub TR; Armstrong SA
Nature; 2006 Aug; 442(7104):818-22. PubMed ID: 16862118
[TBL] [Abstract][Full Text] [Related]
31. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
32. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
33. Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
Li L; Bhatia R
Curr Opin Hematol; 2015 Jul; 22(4):324-9. PubMed ID: 26049753
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
35. Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Muselli F; Peyron JF; Mary D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717629
[TBL] [Abstract][Full Text] [Related]
36. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
37. Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.
González-Herrero I; Vicente-Dueñas C; Orfao A; Flores T; Jiménez R; Cobaleda C; Sánchez-García I
Carcinogenesis; 2010 Jul; 31(7):1292-7. PubMed ID: 20299524
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia stem cell biology.
Crews LA; Jamieson CH
Curr Hematol Malig Rep; 2012 Jun; 7(2):125-32. PubMed ID: 22467334
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.
Zhang H; Li S
Protein Cell; 2013 Mar; 4(3):186-96. PubMed ID: 23483480
[TBL] [Abstract][Full Text] [Related]
40. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
